Morgan Stanley raised the firm’s price target on ResMed (RMD) to $304 from $298 and keeps an Overweight rating on the shares. Ahead of the company’s fiscal Q1 report, the analyst notes that the firm’s Q1 revenue forecast of $1.33B is 1% below the Visible Alpha consensus.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed initiated with an Equal Weight at Wells Fargo
- Resmed’s Strategic Positioning and Growth Prospects: A Buy Recommendation by Laura Sutcliffe
- Resmed’s Strategic Growth and Competitive Edge Support Buy Rating with $300 Price Target
- ResMed U.S. shares initiated with a Buy at Citi
- ResMed participates in a conference call with KeyBanc